SU1704783A1 - Method of preparing powdered drugs - Google Patents
Method of preparing powdered drugs Download PDFInfo
- Publication number
- SU1704783A1 SU1704783A1 SU894709749A SU4709749A SU1704783A1 SU 1704783 A1 SU1704783 A1 SU 1704783A1 SU 894709749 A SU894709749 A SU 894709749A SU 4709749 A SU4709749 A SU 4709749A SU 1704783 A1 SU1704783 A1 SU 1704783A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- aerosil
- box
- powder
- mortar
- theophylline
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims description 3
- 239000003814 drug Substances 0.000 title claims description 3
- 238000000034 method Methods 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 17
- 229910002012 Aerosil® Inorganic materials 0.000 claims abstract description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims abstract description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000278 theophylline Drugs 0.000 claims abstract description 7
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims abstract description 5
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims abstract description 5
- 229960005156 digoxin Drugs 0.000 claims abstract description 5
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims abstract description 5
- CTNPHHZPAJYPFO-PDXBGNJTSA-N (3s,5s,8r,9s,10s,13r,14s,17r)-3-[(2r,4s,5r,6r)-5-[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C=O)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@@H]2[C@H]([C@H](O)[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](CO)O2)O)OC)=CC(=O)OC1 CTNPHHZPAJYPFO-PDXBGNJTSA-N 0.000 claims abstract description 4
- FHIREUBIEIPPMC-UHFFFAOYSA-N K-Strophanthin-beta Natural products O1C(C)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 FHIREUBIEIPPMC-UHFFFAOYSA-N 0.000 claims abstract description 4
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims abstract description 4
- 229960002028 atropine sulfate Drugs 0.000 claims abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 239000011261 inert gas Substances 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000004570 mortar (masonry) Substances 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 229910052573 porcelain Inorganic materials 0.000 description 6
- 239000000203 mixture Substances 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение касаетс технологии лекарственных форм, а именно порошков. Цель изобретени - повышение стабильности при хранении. Лекарственные вещества , выбранные из группы теофиллин, строфантин, дигоксин, атропина сульфат, растирают с аэросилом в атмосфере азота или инертного газа, при этим на 100 частей лекарственного вещества берут 3-9 частей аэросила. 1 табл.The invention relates to the technology of dosage forms, namely powders. The purpose of the invention is to increase storage stability. Medicinal substances selected from the group of theophylline, strophanthin, digoxin, atropine sulfate, are ground with aerosil in an atmosphere of nitrogen or inert gas, with this taking 3-9 parts of aerosil per 100 parts of drug substance. 1 tab.
Description
Изобретение относитс к фармации и касаетс технологии лекарственных форм, а именно порошков.This invention relates to pharmacy and relates to the technology of dosage forms, namely, powders.
Цель изобретени - повышение стабильности при хранении.The purpose of the invention is to increase storage stability.
Изобретение иллюстрируетс следующими примерами.The invention is illustrated by the following examples.
В фарфоровую ступку помещали .485., 1 мг дигоксина и 29,1 мг аэросила. Ступку с пэстиком и препаратом вносили в бокс. После продувани с содержимым аргоном в течение 15 мин растирали смесь в течение 2 мин. Затем бокс разгерметизировали, брали навеску (18,0 мг) дл определени содержани дигоксина. остальную часть порошка пересыпали в бокс и ставили дл хранени , через 10,20, 30 и 60 дней определ ли содержание дигоксина в порогине, которое составило 94,3; 93,5; 93,4 и 93,2% соответственно.In a porcelain mortar were placed .485., 1 mg of digoxin and 29.1 mg of aerosil. Mortar with pestic and drug made into the box. After purging with the contents of argon, the mixture was ground for 15 minutes for 2 minutes. Then the box was unsealed, a sample (18.0 mg) was taken to determine the content of digoxin. the rest of the powder was poured into the box and set for storage, after 10.20, 30 and 60 days the content of digoxin in the threshold was determined, which amounted to 94.3; 93.5; 93.4 and 93.2%, respectively.
Пример 2. В фарфоровую ступку помещали 512.1 мг к-строфантина-/ и 30,7 мг аэросила. Ступку с пестиком и препаратом вносили в бокс и продували азотом в течение 15 мин После этого растирали смесь в течение 2 мин. Затем бокс разгерметизировали , ступку с порошком выносили из бокса и брали навеску (20,5 мг) дл определени содержани строфантина в порошке . Остальную часть порошка пересыпали в бокс и ставили дл хранени . Через 10, 20. 40 и 60 дней определ ли массовую долю строфантина в хран щемс порошке, котора составила 93,8; 93,7; 93,5; 93,0% соответственно .Example 2. In a porcelain mortar, 512.1 mg of c-strophanthin- / and 30.7 mg of aerosil were placed. A mortar with a pestle and a preparation was added to the box and purged with nitrogen for 15 minutes. After that, the mixture was ground for 2 minutes. Then the box was depressurized, the mortar with the powder was taken out of the box and a sample (20.5 mg) was taken to determine the content of strophanthin in the powder. The rest of the powder was poured into the box and set for storage. After 10, 20. 40 and 60 days, the mass fraction of strophanthin in the stored powder was determined, which was 93.8; 93.7; 93.5; 93.0%, respectively.
Пример 3. В фарфоровую ступку помещали 488,0 мг теофиллина и 29,3 мг аэросила. Ступку с содержимым и пестиком помещали в бокс выше указанной марки и продували аргоном в течение 15 мин.Example 3. In a porcelain mortar were placed 488.0 mg of theophylline and 29.3 mg of aerosil. The mortar with the contents and pestle was placed in a box of the above-mentioned mark and purged with argon for 15 minutes.
После этого бокс загерметизировали и растирали смесь в течение 2 мин. Затем бокс разгерметизировали, брали навеску (32,1 мг), обрабатывали нужным количеством воды, отфильтровывали перерастворившийс аэросил и в фильтрате определ ли содержание теофиллина спектрофотомет- рическим методом. Остальное количество приготовленного порошка пересыпали в бокс дл хранени . Через 10, 20, 30 и 60 дней хранени из бокса брали определенные навески порошка дл определени маеИAfter this, the box was sealed and the mixture was ground for 2 minutes. Then the box was depressurized, the sample was taken (32.1 mg), treated with the required amount of water, the reconstituted aerosil was filtered, and the content of theophylline was determined by a spectrophotometric method in the filtrate. The remaining amount of the prepared powder was poured into the storage box. After 10, 20, 30 and 60 days of storage, certain weights of powder were taken from the box to determine
VJVj
еe
vjvj
0000
соwith
спнии доли негИ Иллина в нем, котора со- С1анилз 94.3; 91,1; 93.8; 93.7 и 93,6% соответственно .the back of the share of Illi's negligence in it, which is CIANILS 94.3; 91.1; 93.8; 93.7 and 93.6%, respectively.
П р и м р. р 4. В фарфоровую ступку помещали 515.1 мг атропина сульфата и 3.09 мг аэросила. Ступку с содержимым и пестиком помещали з бокс указанной марки и продували азотом в течение 15 мин. После этого бокс загерметизировали и растирали смесь в течение 2 мин. Затем бокс разгерметизировали , брали навеску порошка из ступки (18,5 мг), обрабатывали ее нужным количеством воды дл получени раствора концентрации моль/л. Аэросил отфильтровывали , а в фильтрате спектрофото- метрическим методом определ ли содержание атропина сульфата. Остальное количество приготовленного порошка пересыпал и в бюкс дл дальнейшего хранени в течение 10, 20, 30 и 60 дней. Массовые доли составили 94.1; 93,2; 92,3; 91,1 и 90,4% соответственно .PRI m p. p 4. In a porcelain mortar, 515.1 mg of atropine sulfate and 3.09 mg of aerosil were placed. The mortar with the contents and pestle was placed in the box of the specified brand and purged with nitrogen for 15 minutes. After this, the box was sealed and the mixture was ground for 2 minutes. Then the box was unsealed, the powder was poured from the mortar (18.5 mg), treated with the necessary amount of water to obtain a solution of mol / L concentration. Aerosil was filtered, and the content of atropine sulfate was determined by a spectrophotometric method in the filtrate. The remaining amount of the prepared powder was poured into the tube for further storage for 10, 20, 30 and 60 days. Mass fraction amounted to 94.1; 93.2; 92.3; 91.1 and 90.4%, respectively.
Пример 5. В одну фарфоровую ступку помещали 251.0 мг теофиллина и 15,1 мг аэросила, во вторую фарфоровую ступку помещали 250.5 мг аскорбиновой кислоты и 15.0мг аэросила. Обе ступки вносили в бокс, герметизировали и продували аргоном в течение 15 мин. После этого растирали каждый компонент в ступке с аэросилом в течение 2 мин, а затем все пересыпали вExample 5. In one porcelain mortar, 251.0 mg of theophylline and 15.1 mg of aerosil were placed, 250.5 mg of ascorbic acid and 15.0 mg aerosil were placed in the second porcelain mortar. Both mortars were placed in a box, sealed and purged with argon for 15 minutes. After this, each component was ground in a mortar with aerosil for 2 min, and then all were poured into
одну ступку и смешивали при растирании еще в течение 2 мин. Образующийс порошок выносили из бокса, брали навеску (38,5 мг) дл анализа, остальную часть порошкаone mortar and mixed by grinding for another 2 minutes The resulting powder was removed from the box, weighed (38.5 mg) for analysis, the rest of the powder
ссыпали в бокс дл хранени . Навеску порошка обрабатывали водой, нерастворившийс аэросил отфильтровывали и определ ли содержание теофиллина в фильтрате спектрофотометрическим методом,piled into storage box. A portion of the powder was treated with water, the undissolved aerosil was filtered, and the content of theophylline in the filtrate was determined by spectrophotometric method,
как описано выше. Через 3, 7, 14 и 30 дней из бокса брали определенные навески порошка дл количественного определени содержани теофиллина в нем. Оно составл ло 47,2; 42,5; 41,4: 39,4 и 38,1 соответственно .as described above. After 3, 7, 14, and 30 days, certain weights of powder were taken from the box to quantify theophylline content in it. It was 47.2; 42.5; 41.4: 39.4 and 38.1, respectively.
Предложенный способ в отличие от известного позвол ет получить более стабильные при хранении порошки, что отражено в таблице.The proposed method, in contrast to the known, allows to obtain powders that are more stable during storage, which is reflected in the table.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894709749A SU1704783A1 (en) | 1989-06-23 | 1989-06-23 | Method of preparing powdered drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894709749A SU1704783A1 (en) | 1989-06-23 | 1989-06-23 | Method of preparing powdered drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1704783A1 true SU1704783A1 (en) | 1992-01-15 |
Family
ID=21456359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU894709749A SU1704783A1 (en) | 1989-06-23 | 1989-06-23 | Method of preparing powdered drugs |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1704783A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2122405C1 (en) * | 1992-11-25 | 1998-11-27 | Наносистемс Л.Л.С. | Method of drug particle preparing |
-
1989
- 1989-06-23 SU SU894709749A patent/SU1704783A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Езерский М.Л., Астраханова М.М. Стабилизаци аэросила некоторых лекарственных смесей. - Фармаци , 1980, № 3, с; 21- 24. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2122405C1 (en) * | 1992-11-25 | 1998-11-27 | Наносистемс Л.Л.С. | Method of drug particle preparing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69105106T2 (en) | FAST SUSPENSABLE PHARMACEUTICAL COMPOSITION. | |
| US4323577A (en) | Aqueous solution of nitroglycerin | |
| JPS5914446B2 (en) | Solid preparation containing nifedipine and its manufacturing method | |
| EA200700173A1 (en) | POROUS TABLETS AS MEDIA FOR LIQUID COMPOSITIONS | |
| EA199700110A1 (en) | COMPOSITION WITH HIGH CONTENT OF ACETAMINOPHEN FOR DIRECT PRESSING | |
| US6291462B1 (en) | Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates | |
| RU98101470A (en) | NEW STABLE MEDICINAL COMPOSITION FOR PRODUCING AEROSOLS OF WORKING GAS | |
| Raggi et al. | Colorimetric determination of acetylcysteine, penicillamine, and mercaptopropionylglycine in pharmaceutical dosage forms | |
| RU1829935C (en) | Method for producing flunarizine-containing composition | |
| SU1704783A1 (en) | Method of preparing powdered drugs | |
| US5532305A (en) | Controlled release preparation for bioactive substances | |
| GB2058562A (en) | Pharmaceutical compositions containing paracetamol and ascorbic acid | |
| AU2009224968B2 (en) | Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate | |
| US20100184870A1 (en) | Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate | |
| Enemar et al. | Growth-promoting effects of ovine somatotropin and prolactin in tadpoles of Rana temporaria | |
| KR910003557B1 (en) | Process for preparing liquid prolonged release pharmaceutical formulations | |
| KR920008060A (en) | Galactomannan derivatives for coating or sealing pharmaceutical actives | |
| JPS5225015A (en) | Process for preparing fine granular drugs | |
| JPS5726613A (en) | Preparation of crystalline freeze-dried pharmaceutical | |
| GB1464467A (en) | Pharmaceutical composition for the treatment of coronary | |
| SU974228A1 (en) | Method of determination isonicotine acidderivatives based drug preparations | |
| EA199800179A1 (en) | Process for preparing solid dosage forms of very low-dose drugs | |
| US4146648A (en) | Chemotherapeutic composition | |
| JPS59101422A (en) | Solid pharmaceutical preparation of nifedipine having improved dissolution property | |
| JPS5612309A (en) | Oral drug containing ubidecarenone |